Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2000

View Archived Issues

Interaction regulating apoptosis could impact cancer therapy development

NF-kappaB implicated in mechanism underlying cachexia

Immtech begins DB-289 human trials for opportunistic infection

D-Pharm's neuroprotective drug candidate nears phase II

Anxiolytic-like effects described for nafadotride in animal model

NPS-1506: a summary of data up to early clinical trials in stroke patients

Preclinical and clinical experience with BMS-204352, a maxi-K channel opener, discussed at EFNS

Tempol exerts short- and long-term protective effects in stroke model

Effects of repeated doses of YF-476 on gastric pH examined in healthy volunteers

Successful treatment of breakthrough pain with intranasal morphine

Sonus refocuses development strategy towards drug delivery, blood substitutes

Clinical trials of new RSV therapeutic VP-14637 commence

FDA approves Novantrone for worsening forms of multiple sclerosis

Extended-release Lescol XL cleared by FDA for cholesterol reduction

Abbott researchers design novel water-soluble K+ channel openers

New agents for diabetes and related conditions emerge from joint research conducted at Japanese labs

Kyorin patents new AMPA receptor antagonists and their use

Novel antiinflammatory/immunomodulatory agents identified at Kowa

Aventis presents several related series of anorectic compounds

Preparation and use of new TK inhibitors as antiangiogenic agents

NIH grant awarded to Novasite to develop technology

Amgen to acquire Kinetix

Intellivax's nasal proteosome flu vaccine enters phase I

Enzyme replacement therapy for MPS VI proceeds to phase I/II

EGF receptor-related research collaboration with M.D. Anderson announced by Enchira

Cholera vaccine moves into phase IIb trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...